Related Experiment Video

Updated: Jun 28, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

[Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population]

Jun-Niao Liu1, Xue-Mei Zhang, Yong-Li Guo

  • 1Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|October 29, 2008
PubMed
Abstract

Insights

Genetic variations in the Mouse double minute 2 (MDM2) gene, but not p53, are linked to increased colorectal cancer risk in a Chinese population. The MDM2 GG genotype showed a significant association with higher cancer susceptibility.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The p53 pathway is vital for preventing cancer by controlling cell cycle arrest and apoptosis.
  • Mouse double minute 2 (MDM2) is a key negative regulator of p53 and is often overexpressed in cancers.
  • Previous studies linked MDM2 and p53 genetic polymorphisms to other cancer types.

Purpose of the Study:

  • To investigate the association between MDM2 and p53 genetic polymorphisms and the risk of colorectal cancer occurrence and progression.
  • To evaluate the combined effects of these polymorphisms on colorectal cancer susceptibility.

Main Methods:

  • Genotyping of 1000 colorectal cancer patients and 1300 controls using PCR-based methods.
  • Analysis of MDM2 promoter (309T>G) and p53 codon 72 (Arg>Pro) polymorphisms.
  • Unconditional logistic regression was used to estimate associations with cancer risk.

Main Results:

  • An increased risk of colorectal cancer was associated with the MDM2 GG genotype (OR=2.06) and TG genotype (OR=1.31) compared to TT.
  • No significant association was found between p53 polymorphisms and colorectal cancer risk.
  • A combined analysis revealed a significantly higher risk (OR=2.75) for individuals with both MDM2 GG and p53 Pro/Pro genotypes compared to MDM2 TT and p53 Arg/Arg.

Conclusions:

  • Genetic polymorphism in the MDM2 gene is associated with susceptibility to colorectal cancer in the Chinese population.
  • The p53 polymorphism does not appear to influence colorectal cancer risk independently.
  • Interactions between MDM2 and p53 polymorphisms may play a role in colorectal cancer development.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...